Marubeni : Entry Into Regenerative Medicine/Drug Discovery and Development Market Partnership with Cyfuse Biomedical K.K.
October 22, 2019 at 10:20 pm EDT
Share
October 23, 2019
Marubeni Corporation
Entry Into Regenerative Medicine/Drug Discovery and Development Market
Partnership with Cyfuse Biomedical K.K.
Marubeni Coporation (hereinafter, "Marubeni") and Cyfuse Biomedical K.K. (hereinafter, "Cyfuse") have signed a partnership agreement to work together toward sales promotion of a new Bio 3-D Printer called "S-PIKE", a product invented by Cyfuse, in Europe and North America.
Regenerative Medicine is being hailed as a solution for such problems as transplant rejection, lack of organ donors and intractable diseases, and has recently been progressing in leaps and bounds. Furthermore, as demand is growing for alternative methods to animal testing and drug screenings before clinical trials, regenerative medicine has gained traction as a tool for drug discovery and development.
Cyfuse is a regenerative medicine startup that invented the 3D Bio-printer method(*1) which is capable of generating steric tissues and organs just from cells. Cyfuse aims to create regenerative cell products, bone and cartilage, vascular, nerve and other organ regeneration. Additionally, Cyfuse has been developing its cell products as a drug discovery and development tool to elucidate disease mechanisms or to evaluate the effectiveness, toxicity, metabolism and other attributes of new drugs.
By entering into the growing market of regenerative medicine and drug discovery and development through its partnership with Cyfuse, Marubeni will use its broad global network as a Diversified Trading Conglomerate to establish new businesses and alliances and contribute to the development of the advanced medical field.
(*1) Cyfuse's platform technology is a unique and innovative. It uses aggregated cells (spheroid) with a diameter of about 0.5 ㎜ is layered on a fine needle to create a three-dimensional structure only with cells without using scaffold. This technology is expected to lead to breakthroughs for regenerative medicine and drug discovery research in a wide range of disease areas.
Company Name : Cyfuse Biomedical K.K.
Address
: ICN Bldg. 5A, 2-27-17, Hongo, Bunkyo-ku, Tokyo, 113-0033, JAPAN
Established
: 2010
Representative
: Shizuka Akieda (Representative Director)
Business
: Development, manufacturing, and sales of regenerative medicine related products.
URL
: http://www.cyfusebio.com/
Attachments
Original document
Permalink
Disclaimer
Marubeni Corporation published this content on 23 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 October 2019 02:19:01 UTC
Marubeni Corporation is a diversified group organized primarily around 12 business segments:
- sale of agricultural products and related services (47% of net sales): sale of agricultural inputs (crop protection products, fertilizers, seeds, etc.), precision farming services, formulation of crop protection products, export of cereals and oilseeds, etc.;
- sale of food products (17.6%);
- production and distribution of oil, gas, alternative energy and electricity (10.4%);
- production of chemicals and petrochemicals (6.4%);
- production of metals and mineral resources (4.9%);
- sale and financing of industrial and construction machinery and equipment (4.6%). The group also develops car sales and tire distribution activities;
- sales of consumer electronics (4.3%). In addition, the group develops real estate development and management activities;
- sale of forest products (2.3%): wood chips and biomass fuel, pulp and waste paper, paper, paperboard, hygiene products, building & construction materials and wood products;
- sale of apparel, accessories, textile and lifestyle products (1.1%);
- management and operation of aircraft and ships (1%);
- development of energy production units and industrial installations (0.3%);
- finance and leasing (0.1%): auto finance, aircraft leasing, aircraft engine leasing, leasing and renting of refrigerated trailers, commercial vehicles and commercial freight railcars, etc.
Net sales are distributed geographically as follows: Japan (37.2%), the United States (42.5%)
MARUBENI CORPORATION 
